CMV-pp65-CTL (Atara/MSKCC)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCMV-pp65-CTL (Atara/MSKCC)
Drug Alias NameCMV-pp65-CTL-Atara-MSKCC
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Virus-specific T Cell therapy
Mechanisms of ActionCytomegalovirus pp65 Antigen modulators
TargetsCytomegalovirus pp65 Antigen
Therapy Area/IndicationsCytomegalovirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesAtara Biotherapeutics IncMemorial Sloan Kettering Cancer Center
Inactive CompaniesN/A
Active IndicationsCytomegalovirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A